| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |